Goserelin's Versatile Roles in Benign and Malignant Gynecological Conditions Systematically Reviewed

Many hormone-dependent gynecological conditions significantly impact women's health, often requiring interventions to suppress ovarian function. Current standard-of-care for conditions like endometriosis and uterine fibroids frequently involves hormonal manipulation, but long-term management can be challenging due to side effects or incomplete efficacy. Gonadotropin-releasing hormone (GnRH) agonists, like goserelin, offer a mechanism to achieve pituitary downregulation and ovarian suppression, thereby reducing estradiol and progesterone levels to postmenopausal ranges. This approach effectively targets the hormonal drivers of these diseases, providing a crucial therapeutic avenue for managing a spectrum of gynecological disorders.

This comprehensive review systematically consolidated the established and emerging clinical applications of Goserelin across a broad spectrum of benign and malignant gynecological conditions. Researchers analyzed three decades of literature, focusing on its mechanism of action, efficacy, and safety profile in various indications. The review aimed to underscore the peptide's clinical versatility by examining its utility in approved indications, such as endometriosis and uterine fibroids, as well as exploring its potential in more recent research areas like adenomyosis and different types of female cancers. The methodology involved a thorough synthesis of existing evidence to highlight GnRH receptor desensitization and subsequent hormonal suppression as the core therapeutic principle.

Goserelin's mechanism of action, centered on sustained GnRH receptor desensitization, consistently leads to pituitary downregulation and ovarian suppression, effectively reducing estradiol and progesterone to postmenopausal levels. This review confirmed Goserelin's well-established efficacy and safety profile across its approved gynecological indications. Key established uses include the management of endometriosis, treatment of uterine fibroids, acting as an agent for endometrial thinning prior to procedures, and serving as an agent for ovarian downregulation before assisted reproduction. Emerging research highlights its potential utility in other challenging gynecological diseases. > Goserelin is increasingly being explored for its roles in adenomyosis and various types of female cancers, suggesting a broader therapeutic scope beyond its current approved indications. Furthermore, the review identified scenarios where Goserelin could be a valuable tool in multi-disciplinary gynecologic management, showcasing its remarkable clinical versatility.